Open an account

HeartSciences

HSCS · NASDAQ

$3.13+$0.06 (+1.95%)TodayMarket closed ·
Prev close $3.07

About HSCS

HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. The company is headquartered in Southlake, Texas and currently employs 15 full-time employees. The company went IPO on 2022-06-15. The firm has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. The company delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

Employees
15
Headquarters
Southlake, Texas
Listed
Jun 15, 2022
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
heartsciences.com

HSCS key statistics

Market cap
15.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
238.49K
Volume
42.82K
Open price
$3.07
High today
$3.32
Low today
$3.00
52 Week high
$5.25
52 Week low
$1.63

HeartSciences (HSCS) at a glance

HeartSciences (HSCS) last traded at $3.13, with a market cap of 15.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.00 and $3.32. The current price is 4.3% above the day's low and 5.7% below its high.

Volume so far is 42.82K shares, below the average of 238.49K shares a day.

Over the past year HeartSciences has ranged from $1.63 to $5.25, and now sits 41% of the way up that range.

HeartSciences met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY27 it reported -$0.86 per share against an estimate of -$0.7395.

The average analyst price target is $10.20, 225.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $10.20
Low
$8.08
Now
$3.13
High
$12.60

HSCS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 26.0% on average.

  1. Q2 FY25: reported -$2.27 per share against an estimate of -$2.48
  2. Q3 FY25: reported -$2.57 per share against an estimate of -$2.42
  3. Q4 FY25: reported -$1.88 per share against an estimate of -$2.30
  4. Q1 FY26: reported -$1.58 per share against an estimate of -$1.94
  5. Q2 FY26: reported -$0.85 per share against an estimate of -$2.01
  6. Q3 FY26: reported -$0.63 per share against an estimate of -$0.867
  7. Q4 FY26: reported -$0.87 per share against an estimate of -$0.7446
  8. Q1 FY27: reported -$0.86 per share against an estimate of -$0.7395

HSCS news

  • Press releaseBusiness Wire

    Fortitude Secures Priority Supply Allocation for BITMAIN’s Next-Generation Zcash Mining Equipment, Announces $100 Million Non-Binding Purchase Commitment, and Additional Upsizing of DCG Credit Facility and Available ZEC Funding from DCG

  • Press releaseBusiness Wire

    Fortitude Appoints Kimberly Pittman as Chief Legal Officer

  • Press releaseBusiness Wire

    Fortitude Announces Amendment to Existing DCG Credit Facility, Increasing Commitment by $24 Million and Providing for Future Funding in ZEC

  • Press releaseBusiness Wire

    Fortitude Appoints Jaime Leverton as Chief Executive Officer

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Press releaseBusiness Wire

    Fortitude Provides Second Quarter 2026 Financial and Operating Highlights

  • Press releaseBusiness Wire

    Fortitude Completes Acquisition of 12.5 MW Prosser, Nebraska Facility

  • Press releaseBusiness Wire

    Fortitude Purchases 9,000 Bitmain Antminer Z15 Pro Units, Deepening Commitment to the Zcash Ecosystem

Similar companies

Companies in the same industry as HeartSciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.